Publication,

China Beauty - How Building a China Business Can Sweeten a Private Equity Exit

CN | EN
Current site :    CN   |   EN
Australia
Belgium
China
China Hong Kong SAR
Germany
Italy
Japan
Singapore
Spain
UAE
United Kingdom
United States
Global

In 2021, China finally ended mandatory animal testing for most types of cosmetics products. 

However, it is not only rabbits that have reason to rejoice. 

The beauty industry is BIG. Estimated to be globally $483 billion in 2020 and despite COVID, lockdowns etc. it actually grew to an estimated $511 billion in 2021. China is a big part of this growth story.

The beauty industry has a varied ecosystem – dominated by giants like L'Oreal and Procter & Gamble but also having a vibrant range of medium and small businesses which constantly rise and fall – but also inject innovation and dynamism.

Increasingly, private equity and funds invest in high potential beauty brands with the view of a trade sale to a giant, a listing or a secondary buyout. These hip and young brands intrinsically capture society's Zeitgeist – as a result they are invariably cruelty free. And this is a problem for their private equity investors – how can an exit be optimized if the largest growth market in the world is off limits?

DOWNLOAD PUBLICATION
China Beauty
How Building a China Business Can Sweeten a Private Equity Exit

Download

1.39MB, 16 Pages

LATEST THINKING
Insight
New regulations in China designed to encourage innovation in clinical trials have made it easier to test human samples in a lab setting.

19 May 2022

Publication
Since 2017, KWM has issued the Series, Think Tank Report: Law and Practice under the Belt and Road Initiative. As the fifth instalment of the Series, this pamphlet comprises two parts: “Overview” and “Introduction by Countries”. Authored by KWM lawyers focusing on investment, financing, construction and projects, M&A, trade, compliance, and dispute resolution, this pamphlet will present you our experience and insights from different perspectives.

14 May 2022

Insight
Under the Chinese medical device regulatory regime, as filing/registration is compulsory prior to marketization, the legality of use of unregistered in vitro diagnostics reagents (“IVD”) in laboratory-developed testing (“LDT”) has been in a grey area for a long time.

10 May 2022